NEW YORK (TheStreet) -- Shares of Cerus (CERS) were climbing 16.47% to $4.91 on heavy trading volume late-afternoon Friday after the biomedical products company late yesterday posted a narrower-than-expected loss for the 2016 third quarter and provided upbeat full-year revenue guidance.
After yesterday's closing bell, Concord, CA-based Cerus posted an adjusted loss of 14 cents per share, narrower than analysts expectations of a loss of 17 cents per share.
Revenue grew 10.2% year-over-year to $10.18 billion, but fell short of Wall Street's projected $10.20 billion.
The company also backed its full-year revenue forecast of $37.0 billion to $40.0 billion. The FactSet consensus is for $39.4 billion.
About 3.62 million of the company's shares changed hands so far today vs. its average 30-day volume of 794,594 shares per day.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
The team rates Cerus as a Sell with a ratings score of D. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share.
You can view the full analysis from the report here: CERS